Search Results - "Chalermpalanupap, Natty"

  • Showing 1 - 6 results of 6
Refine Results
  1. 1

    Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial by Lipton, Richard B., Nahas, Stephanie J., Pozo-Rosich, Patricia, Bilchik, Tanya, McAllister, Peter, Finnegan, Michelle, Liu, Yingyi, Chalermpalanupap, Natty, Dabruzzo, Brett, Dodick, David W.

    Published in Journal of headache and pain (21-05-2024)
    “…Background Atogepant is an oral calcitonin gene–related peptide receptor antagonist approved for the preventive treatment of migraine in adults. These analyses…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4
  5. 5

    Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine by Ailani, Jessica, Gandhi, Pranav, Lalla, Anjana, Halker Singh, Rashmi, McAllister, Peter, Smith, Jonathan H., Dabruzzo, Brett, Chalermpalanupap, Natty, Kelton, Kari, Nahas, Stephanie J.

    Published in Headache (01-11-2024)
    “…Objective To estimate the number needed to treat and cost per additional responder for atogepant and rimegepant versus placebo for the preventive treatment of…”
    Get full text
    Journal Article
  6. 6

    Focus on the Locus: Elucidating the Roles of Tau Pathology and the Locus Coeruleus in Alzheimer's Disease by Chalermpalanupap, Natty Termpanit

    Published 01-01-2017
    “…Alzheimer's disease (AD) is an insidious, progressive neurodegenerative disorder with societal and financial burdens that are escalating every single day…”
    Get full text
    Dissertation